| pubmed-article:20956986 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20956986 | lifeskim:mentions | umls-concept:C0021051 | lld:lifeskim |
| pubmed-article:20956986 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:20956986 | lifeskim:mentions | umls-concept:C1519889 | lld:lifeskim |
| pubmed-article:20956986 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20956986 | pubmed:dateCreated | 2011-3-17 | lld:pubmed |
| pubmed-article:20956986 | pubmed:abstractText | Numerous human immunodeficiency virus (HIV)-1 vaccines have been developed over the last three decades, but to date an effective HIV-1 vaccine that can be used for prophylactic or therapeutic purposes in humans has not been identified. The failures and limited successes of HIV-1 vaccines have highlighted the gaps in our knowledge with regard to fundamental immunity against HIV-1 and have provided insights for vaccine strategies that may be implemented for designing more effective HIV-1 vaccines in the future. Recent studies have shown that robust mucosal immunity, high avidity and polyfunctional T cells, and broadly neutralizing antibodies are important factors governing the induction of protective immunity against HIV-1. Furthermore, optimization of vaccine delivery methods for DNA or live viral vector-based vaccines, elucidating the immune responses of individuals who remain resistant to HIV-1 infections and also understanding the core immune responses mediating protection against simian immunodeficiency viruses (SIV) and HIV-1 in animal models following vaccination, are key aspects to be regarded for designing more effective HIV-1 vaccines in the future. | lld:pubmed |
| pubmed-article:20956986 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20956986 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20956986 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20956986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20956986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20956986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20956986 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20956986 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20956986 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:20956986 | pubmed:issn | 1440-1711 | lld:pubmed |
| pubmed-article:20956986 | pubmed:author | pubmed-author:RamshawIan... | lld:pubmed |
| pubmed-article:20956986 | pubmed:author | pubmed-author:RanasingheCha... | lld:pubmed |
| pubmed-article:20956986 | pubmed:author | pubmed-author:JacksonRonald... | lld:pubmed |
| pubmed-article:20956986 | pubmed:author | pubmed-author:WijesundaraDa... | lld:pubmed |
| pubmed-article:20956986 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20956986 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:20956986 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20956986 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20956986 | pubmed:pagination | 367-74 | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:meshHeading | pubmed-meshheading:20956986... | lld:pubmed |
| pubmed-article:20956986 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20956986 | pubmed:articleTitle | Human immunodeficiency virus-1 vaccine design: where do we go now? | lld:pubmed |
| pubmed-article:20956986 | pubmed:affiliation | Department Emerging Pathogens and Vaccines, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia. danushka.wijesundara@anu.edu.au | lld:pubmed |
| pubmed-article:20956986 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20956986 | pubmed:publicationType | Review | lld:pubmed |
